Volker Koscielny, new Chief Medical Officer and new member of the Management Board at Almirall
• Volker Koscielny will lead the overall medical strategy while providing guidance to the Medical department
• He will report directly to CEO, Peter Gunter, and be a member of the Management Board
• The new Chief Medical Officer has a particular interest in understanding patient needs and demonstrating the value of medicines to patients and healthcare systems in the real world
• Launches of innovative products and the build up of the pipeline are core to Almirall’s strategy
Almirall, S.A. (ALM) has announced the appointment of Volker Koscielny as the new Chief Medical Officer and member of the Management Board of the company.
In his new role, Volker Koscienly will report directly to Peter Guenter, Chief Executive Officer of Almirall, and will be driving the overarching Medical Affairs strategy providing guidance to the Medical department, fostering medical innovation and ensuring safe and appropriate use of all our products.
Reinforcing the medical department is a strategic imperative given our launches of increasingly innovative products and our exciting pipeline”, explained Peter Guenter, Chief Executive Officer, Almirall. “Volker will join us with experience from leading pharmaceutical companies and with extensive experience in dermatology. Being able to attract somebody of the caliber of Volker underlines Almirall’s attractiveness".
In his last position as Vice President Medical Affairs at Celgene Worldwide Markets (ex-US), based in Switzerland, Volker was instrumental in designing and building the inflammation franchise up from inception and for supporting the ongoing development and launch of Apremilast in plaque psoriasis. Moreover, he played a key role in developing and executing the ex-US real world evidence study programme, that underpinned the success of Apremilast in Europe today.
Before joining Celgene, Volker held positions of increasing seniority in several pharmaceutical companies both in medical and commercial positions in the UK, France and South Africa having local and regional responsibilities across multiple therapeutic areas.
Volker has a particular interest in understanding patient needs and in demonstrating the value of medicines to patients and healthcare systems in the real world. His solid clinical, academic and scientific background, together with his experience in leading large teams and his results orientated mindset, will provide Almirall with a fresh and valuable perspective.
“There is huge unmet need in medical dermatology, with many diseases lacking effective and innovative therapies. I am privileged to be joining an organization that is committed to addressing these areas, aiming to make significant difference to patients’ lives. Almirall today has one of the most exciting and innovative pipelines in medical dermatology and I am looking forward to be joining a team of top professionals to deliver the promise of the product pipeline”, added Dr. Koscielny.
Volker trained as a doctor at the Charité in Berlin - one of the largest university hospitals in Europe - and practiced internal medicine in Germany, his home country. He holds a doctorate in Neuropathology and an MBA from the University of Durham (UK). He will be based in Barcelona, Spain.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.
The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.
Valvanera Lecha / firstname.lastname@example.org
Deva Salas / email@example.com
Tel: (+34) 91 563 77 22 Investors & Corporate Communications contact:
Pablo Divasson del Fraile
Tel: (+34) 93 291 3087